IC
NTLA icon

Ikarian Capital’s Intellia Therapeutics NTLA Stock Holding History

Ikarian Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-294,400
Closed -$47.7M – 245
2021
Q2 		$47.7M Buy
+294,400
New +$22.9M 3.85% 3

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Ikarian Capital's NTLA Position: Q2 2022 in Review

Ikarian Capital sold out of Intellia Therapeutics (NTLA) in Q2 2022, closing a stake of 47,408 shares — an estimated $3.44M sold.

Ikarian Capital first reported a position in NTLA in Q1 2020 and held it in 2 quarters. The position peaked at $3.44M in Q1 2022. 299 funds tracked by Wall St. Rank hold NTLA as of Q2 2022.

  • Ikarian Capital reported no remaining Intellia Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Ikarian Capital sold 47,408 Intellia Therapeutics shares in Q2 2022, an estimated $3.44M.
  • Ikarian Capital first reported a position in Intellia Therapeutics in Q1 2020 and held it in 2 quarters.
  • Ikarian Capital's Intellia Therapeutics position peaked at $3.44M in Q1 2022.
  • 299 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.